It is indicated for the treatment of patients with SMA with a bi-allelic mutation in the SMN1 gene and a clinical diagnosis of type 1 SMA, or patients with SMA with a bi-allelic mutation in the SMN1 gene and up to three copies of the SMN2 gene [10]. This evidence concerns the gene SMN2 and spinal muscular atrophy, type 1.